Ovarian Cancer

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses clinical trial endpoints and individualizing treatment in patients with ovarian cancer.

Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial.

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the identification and treatment of ovarian cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.

Mark A. Morgan, MD, discusses the role of robotic surgery in gynecologic cancer.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.

Russell J. Schilder, MD, discusses the GOG-9929 trial.

Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an overview of screening for ovarian cancer.

Michael Birrer, MD, PhD, discusses the role of PARP inhibitors in ovarian cancer.

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an update on targeted therapies for the treatment of patients with ovarian cancer.

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

A phase III clinical program to investigate olaparib as a treatment for patients with BRCA-mutated ovarian cancer marks a step forward in the revived development of an agent that was once left on the sidelines.

Measuring CA-125, the protein that predicts ovarian cancer recurrence, has shown promise as a screening tool for the disease.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

A study shows that a new chemoresponse assay improves the overall survival and progression-free survival of patients with recurrent ovarian cancer while helping clinicians individualize care for those patients.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses screening for cervical cancer.

Jane Robertson, MD, Global Product Vice President at AstraZeneca, describes the mechanism of action of the PARP inhibitor olaparib.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

The risk of developing ovarian cancer has been linked to several factors including family history, age, and pregnancy history. In the U.S., ovarian cancer accounts for 3% of all cancer in women.

The next-generation PI3 kinase (PI3K) inhibitor GDC-0032 has shown signs of efficacy in patients with advanced cancers that were mutated for the PI3K alpha gene.